Blue rubber bleb nevus syndrome

被引:12
作者
John M. Andersen
机构
[1] University of Texas Southwestern Medical School,Department of Pediatrics, Division of Pediatric Gastroenterology
[2] Children’s Medical Center of Dallas,undefined
关键词
Omeprazole; Octreotide; Lansoprazole; Vascular Malformation; Main Drug Interaction;
D O I
10.1007/s11938-001-0008-4
中图分类号
学科分类号
摘要
Venous malformations of blue rubber bleb nevus syndrome (BRBNS) may involve any area of the gastrointestinal tract.Gastrointestinal blood loss and anemia brings these patients to the attention of gastroenterologists.Effective treatment of these malformations throughout the gastrointestinal tract requires aggressive management to ultimately decrease blood loss and restore the patient’s hemoglobin to a near-normal level.Treatment of patients with BRBNS includes supportive measures, endoscopic ablation, and surgery.Supportive therapy consists of proton pump inhibitors and octreotide to decrease blood loss, iron replacement, and blood transfusions.The effective management of patients with anemia demands aggressive treatment of venous malformations in the small bowel. This requires a collaboration between the surgeon and the therapeutic endoscopist, ie, laparotomy and excision of larger lesions with surgically assisted enteroscopy and thermal ablation of smaller lesions via enterotomy.There is no effective systemic therapy for treatment of the vascular malformations in patients with BRBNS.
引用
收藏
页码:433 / 440
页数:7
相关论文
共 47 条
[1]  
Oranje AP(1986)Blue rubber bleb nevus syndrome Ped Derm 3 304-310
[2]  
Mulliken JB(1982)Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics Plast Reconstr Surg 69 412-422
[3]  
Glowacki J(1999)Clinical portrait of blue rubber bleb nevus syndrome Gastroenterology 116 A877-A877
[4]  
Elizondo BJ(1996)Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2 Cell 87 1181-1190
[5]  
Burdick SJ(2000)Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability, and dose requirements. International pediatric omeprazole study group J Pediatr 137 800-807
[6]  
Andersen JM(1999)Stability of suspension formulations of lansoprazole an omeprazole Am J Health Syst Pharm 94 1813-1817
[7]  
Vikkula M(2000)Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate Aliment Pharmacol Ther 14 887-892
[8]  
Boon LM(1991)treatment of bleeding due to diffuse angiodysplasia of the small intestine Eur J Gastroenterol Hepatol 3 785-787
[9]  
Carraway III KL(1995)Octreotide in the treatment of bleeding gastrointestinal vascular malformations Gastroenterology 110 353-353
[10]  
Hassell E(1998)Use of octreotide for the treatment of severe gastrointestinal bleeding in children J Pediatr Gastroenterol Nutr 26 356-359